Prelude Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
OrbiMed Advisors reports a change in beneficial ownership of Prelude Therapeutics following a recent public offering.
NASDAQ
Baker Bros. Advisors reported an increased beneficial ownership of 15.5% in Prelude Therapeutics following a recent public offering.
NASDAQ
SCHEDULE 13D/A: Baker Bros. Advisors Amends Stake in Prelude Therapeutics, Appoints New Director to Board
Baker Bros. Advisors has filed an amendment to its Schedule 13D, confirming its 23.5% beneficial ownership in Prelude Therapeutics Inc. and announcing a change in its board representation with Dr. Paul C. Scherer joining and Julian C. Baker stepping down.